Rocket Pharmaceuticals: Can The AAV9 Cardiovascular Pipeline Justify The Current Valuation?
Rocket Pharmaceuticals Inc RCKT
$3.11
▼ -3.12%
($-0.10)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$3.19
Prev Close
$3.21
Day Range
$3.05 – $3.21
52W Range
$2.53 – $5.45
Market Cap
$339.59M
Beta
0.47
EPS (TTM)
$-1.88
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-02-18 |
| Shares Out. | 109,190,000 |
| Website | rocketpharma.com/ ↗ |
| Phone | 13026365400 |
| Employees | 202 |
| Net Income | -$48.8M |
| Free Cash Flow | -$179.8M |
| Total Assets | $285.4M |
| Total Liabilities | $47.4M |
| Equity | $238.0M |
About Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Rocket Pharmaceuticals Inc is a publicly traded company under the ticker symbol RCKT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-07-01)